Abstract
SM17, a new IL-17RB-targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have